Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC3141 in severe COVID-19 pneumonia
NCT04880694Phase 2Completed
- Sponsor
- Grand Medical Group AG
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of STC3141 in COVID-19 pneumonia, sponsored by Grand Medical Group AG. Started May 2021; status: completed.
02
Drugs
STC3141
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04880694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880694.